4//SEC Filing
Kovacs Shane William Charles 4
Accession 0001415889-24-029025
CIK 0001750284other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 7:53 PM ET
Size
11.3 KB
Accession
0001415889-24-029025
Insider Transaction Report
Form 4
Kovacs Shane William Charles
CH. OPERATING & FINANCIAL OFF.
Transactions
- Award
Common Stock
2024-12-09+68,250→ 578,708 total - Sale
Common Stock
2024-12-10$9.37/sh−16,803$157,444→ 561,905 total - Sale
Common Stock
2024-12-11$8.66/sh−17,950$155,447→ 543,955 total - Sale
Common Stock
2024-12-11$9.39/sh−406$3,812→ 543,549 total
Footnotes (5)
- [F1]On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 105,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
- [F2]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F3]The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.87 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
Related Parties
1- filerCIK 0001579397
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 7:53 PM ET
- Size
- 11.3 KB